Similar articles

• [Clinical pharmacology of a new hypotensive drug with peripheral vasodilating action (ISF 2123); effects of acute intravenous administration in hypertensive patients].

  Terzoli L, Bianchini C, Cornelli U, Sala C, Leonetti G, Zanchetti A. Terzoli L, et al. Boll Soc Ital Cardiol. 1977;22(7):1053-6. Boll Soc Ital Cardiol. 1977. PMID: 618241 Italian. No abstract available.
• Comparison of the antihypertensive activity of cadralazine (ISF 2469) and dihydralazine during chronic treatment.

  Strocchi E, Costa FV, Caldari R, Malini PL, Marata AM, Parini J, Ambrosioni E. Strocchi E, et al. Int J Clin Pharmacol Ther Toxicol. 1983 Oct;21(10):519-23. Int J Clin Pharmacol Ther Toxicol. 1983. PMID: 6642790 Clinical Trial.
• [Clinical studies on the treatment of hypertension using Disotat].

  Fröhling P, Kautzsch G. Fröhling P, et al. Z Arztl Fortbild (Jena). 1977 Jan 1;71(1):13-6. Z Arztl Fortbild (Jena). 1977. PMID: 324148 Clinical Trial. German. No abstract available.
• [Antihypertensive drugs: effects, undesired secondary effects and pharmacological interactions].

  Bocchinfuso V. Bocchinfuso V. Clin Ter. 1981 Jul 15;98(1):87-91. Clin Ter. 1981. PMID: 7018825 Review. Italian. No abstract available.
• Evaluation of the cerebral effects of antihypertensive medication.

  Callender JS. Callender JS. Eur Heart J. 1988 May;9 Suppl G:59-63. doi: 10.1093/eurheartj/9.suppl_g.59. Eur Heart J. 1988. PMID: 3042420 Review. No abstract available.